Yunjung H Shin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yunjung H Shin has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Emily Aboujaoude
Rutgers University Ernest Mario School of Pharmacy, USA
1 shared publication- Gee Youn (Geeny) Kim
Affiliations Division of Oncology, Hackensack University Medical Center, Hackensack, NJ, United States of America, Department of Pharmacy Practice, Ernest Mario School of Pharmacy at Rutgers University, Piscataway, NJ, United States of America
1 shared publication - Jiyeon Joy Park
Department of Pharmacy, Englewood Health, Englewood, NJ, USA
1 shared publication Marc G Sturgill
Rutgers University Ernest Mario School of Pharmacy, USA
1 shared publication- Xiaofan Tian
Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield Connecticut USA
1 shared publication
Latest Publications
- 29 September 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (1) , 159-174
Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches
The most common adverse event associated with chimeric antigen receptor T-cell therapy is cytokine release syndrome, which is characterized by fever, hypoxia, and hypotension in varying degrees of severity. In severe cases, cytokine release syndrome can result in life-threatening symptoms such as multi-organ failure. The widely accepted first-line therapy for cytokine release syndrome management is tocilizumab with or without corticosteroids, but there is very limited guidance on the proper management of patients unresponsive to this regimen. There are emerging strategies that target cytokine release syndrome through novel mechanisms, showing promise in treating or preventing severe cytokine release syndrome. Although further clinical investigation is necessary to assess the applicability of the emerging approaches, these exploratory therapies may shape the future landscape of chimeric antigen receptor T-cell induced cytokine release syndrome management. This review article provides a comprehensive overview of the current and emerging therapies for the management of chimeric antigen receptor T-cell induced cytokine release syndrome, especially cases that are refractory to tocilizumab and steroids.
- 29 September 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 28 (1) , 159-174
Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches
The most common adverse event associated with chimeric antigen receptor T-cell therapy is cytokine release syndrome, which is characterized by fever, hypoxia, and hypotension in varying degrees of severity. In severe cases, cytokine release syndrome can result in life-threatening symptoms such as multi-organ failure. The widely accepted first-line therapy for cytokine release syndrome management is tocilizumab with or without corticosteroids, but there is very limited guidance on the proper management of patients unresponsive to this regimen. There are emerging strategies that target cytokine release syndrome through novel mechanisms, showing promise in treating or preventing severe cytokine release syndrome. Although further clinical investigation is necessary to assess the applicability of the emerging approaches, these exploratory therapies may shape the future landscape of chimeric antigen receptor T-cell induced cytokine release syndrome management. This review article provides a comprehensive overview of the current and emerging therapies for the management of chimeric antigen receptor T-cell induced cytokine release syndrome, especially cases that are refractory to tocilizumab and steroids.